KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication

Developers should provide training for staff to support use of the technology.

The evidence generation process is most likely to succeed with dedicated research staff to reduce the burden on NHS staff, and by using a suitable real-world data source to collect information when possible.

Evidence generation should be overseen by a steering group including researchers, commissioners, practitioners and representatives with experience working with or caring for people with psychosis or taking antipsychotic medication.

Evidence generation should ideally be across multiple centres. Contributing services or centres should be chosen to maximise the generalisability of evidence generated, or to improve data collection for any relevant subgroups.

Careful planning of approaches to information governance is vital.

It will not be possible to collect data for people having antipsychotic medication who are unable to give informed consent.

KardiaMobile 6L needs to connect to the internet to transmit electrocardiogram (ECG) data to healthcare professionals. This may not be possible for some home visits.

Saving and sending information could be a risk to data protection and information governance if not done correctly and with encrypted NHS mobile devices.

Calculations from 12-lead ECG devices could vary, for example, because of different machine calibrations. Quality assurance could be provided by verifying a sample of QTc results from a 12-lead ECG device with manual calculation.

Currently, QTc is measured manually by healthcare professionals when using KardiaMobile 6L. Availability of validated software for automatic QTc measurement can reduce time for testing and reporting.